Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash & Current Investments: 2010-2025

Historic Cash & Current Investments for Iovance Biotherapeutics (IOVA) over the last 9 years, with Sep 2025 value amounting to $300.8 million.

  • Iovance Biotherapeutics' Cash & Current Investments rose 83.23% to $300.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 24.94%. This contributed to the annual value of $323.8 million for FY2024, which is 15.69% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Cash & Current Investments stood at $300.8 million, which was down 0.13% from $301.2 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Cash & Current Investments ranged from a high of $626.3 million in Q1 2023 and a low of $164.2 million during Q3 2024.
  • In the last 3 years, Iovance Biotherapeutics' Cash & Current Investments had a median value of $301.2 million in 2025 and averaged $323.0 million.
  • In the last 5 years, Iovance Biotherapeutics' Cash & Current Investments crashed by 54.57% in 2024 and then skyrocketed by 83.23% in 2025.
  • Quarterly analysis of 3 years shows Iovance Biotherapeutics' Cash & Current Investments stood at $279.9 million in 2023, then grew by 15.69% to $323.8 million in 2024, then surged by 83.23% to $300.8 million in 2025.
  • Its last three reported values are $300.8 million in Q3 2025, $301.2 million for Q2 2025, and $359.7 million during Q1 2025.